TRDA experienced a dramatic financial deterioration with revenue collapsing 87.9% from $210.8M to $25.4M and swinging from $47M operating income to a $157.9M operating loss.
This represents a fundamental shift in the company's financial profile, suggesting either the loss of a major revenue source or completion of a significant one-time transaction in the prior year. The magnitude of these changes indicates potential business model disruption or major operational restructuring that investors need to investigate immediately.
TRDA's financials show severe deterioration across all key metrics, with revenue plummeting 87.9% and the company swinging from profitability to massive losses, including a $157.9M operating loss and $143.8M net loss. Operating cash flow burn more than tripled to -$128.5M while the balance sheet contracted significantly, with current assets falling 30.4% to $306.3M and stockholders' equity declining 28.6%. Despite the reduced liabilities, this financial profile suggests a biotech company that likely completed a major partnership or licensing deal in the prior year and has now returned to typical R&D cash burn mode, raising questions about runway and future funding needs.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 319% — review whether driven by operations, interest costs, or non-recurring items.
Operating cash flow fell 209.2% — earnings quality concerns; investigate working capital changes and non-cash items.
Revenue declined 87.9% — significant demand weakness or market share loss warrants investigation.
Capex reduced 67% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Current liabilities reduced — improved short-term financial position and working capital health.
Current assets declined 30.4% — monitor working capital adequacy and short-term liquidity.
Equity decreased 28.6% — buybacks or losses reducing book value, monitor solvency ratios.
Total assets contracted 28.3% — asset sales, write-downs, or balance sheet optimization underway.
Liabilities reduced 27% — deleveraging improves balance sheet strength and financial flexibility.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →